



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2143500 C 2007/04/24

(11)(21) **2 143 500**

(12) **BREVET CANADIEN  
CANADIAN PATENT**

(13) **C**

(22) Date de dépôt/Filing Date: 1995/02/27

(41) Mise à la disp. pub./Open to Public Insp.: 1995/08/29

(45) Date de délivrance/Issue Date: 2007/04/24

(30) Priorité/Priority: 1994/02/28 (DEP 4406424.1)

(51) Cl.Int./Int.Cl. *A61K 47/32* (2006.01),  
*A61K 9/00* (2006.01), *A61K 9/20* (2006.01)

(72) Inventeurs/Inventors:  
PENNERS, GUNTHER, DE;  
LUSTIG, KLEMENS, DE;  
GEHR, JORG PETERSEN-VON, DE

(73) Propriétaire/Owner:  
BAYER AKTIENGESELLSCHAFT, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : FORMES PHARMACEUTIQUES EXPANSIBLES

(54) Title: EXPANDABLE PHARMACEUTICAL FORMS

(57) Abrégé/Abstract:

The present invention relates to administration forms having a relatively long gastric residence time, in the preparation of which mixtures of polymers containing lactam groups and polymers containing carboxyl groups are used, and which are distinguished both by marked swelling properties and by high dimensional stability in the swollen state.

2143500

Expandable pharmaceutical forms

A b s t r a c t

The present invention relates to administration forms having a relatively long gastric residence time, in the preparation of which mixtures of polymers containing lactam groups and polymers containing carboxyl groups are used, and which are distinguished both by marked swelling properties and by high dimensional stability in the swollen state.

2143500

Fig. 1




Fig. 2




Fig. 3






Fig. 4



Patent Agents  
Fetherstonhaugh & Co.

2143500

Fig. 5



Patent Agents  
Fetherstonhaugh & Co.

The present invention relates to mixtures of polyvinyl-lactams and polyacrylates in the preparation of pharmaceutical systems having controlled release of active compound, which are characterized in that they swell  
5 strongly in the aqueous environment of the stomach and reside in the stomach for a relatively long time. Optionally, the gastric residence time of the system according to the invention can also be affected by additional incorporation of a gas-forming mixture, as the  
10 gas formed reduces the density of the system, by means of which it floats on the stomach contents and thus cannot very easily reach the pylorus, which is at a lower level.

In comparison with the administration of a number of rapidly releasing individual doses at certain intervals,  
15 the administration of an individual dose of a medicament from which the active compound is released in a controlled manner over a prolonged period (sustained-release formulation) has the advantage that over a prolonged period a constant and uniform blood level of the active  
20 compound is guaranteed. In pharmacy, sustained-release formulations of all sorts of types are known. There are, for example, sustained-release formulations which are based on the controlled erosion of a matrix containing active compound or those from which a water-soluble  
25 active compound is released by controlled diffusion through one or more polymer layers surrounding the formulation. In another sustained-release administration

form, the controlled release is based on displacement of a layer containing active compound from the osmotically active administration form surrounded by a water-permeable membrane as a result of osmotic water  
5 absorption. Pressure equalization or release of active compound in this case takes place through a hole in the membrane.

The sustained-release administration forms briefly described above, however, are only utilizable for active  
10 compounds which are absorbed effectively in all regions of the gastrointestinal tract. They are unsuitable for active compounds which on account of their physicochemical properties or due to microbial degradation have so-called absorption windows, i.e. are only  
15 absorbed in certain regions of the gastrointestinal tract (GI tract), because they pass through the gastrointestinal tract continuously and their residence time in the absorbing part of the GI tract is thus too short to guarantee a long-term action. Examples of  
20 substances whose bioavailability is strongly dependent on the local physiology in the GI tract and which preferably are absorbed in the higher sections of the intestine are ciprofloxacin and nimodipine. Ciprofloxacin is readily soluble in the acidic environment of the stomach. In the  
25 intestine, where neutral to slightly alkaline pH conditions prevail, however, precipitation of the active compound occurs, which adversely affects absorption in the lower sections of the intestine. Nimodipine is degraded by the bacterial flora prevailing in the colon,

and can therefore only be effectively absorbed in the upper region of the intestine. Further active compounds which have absorption windows in the upper GI tract are captopril and ranitidine. Other active compounds in turn,  
5 such as, for example, certain antacids and pepstatin, are locally active and can display their action only if they are released at the site of action, the stomach.

In view of the above explanations, it is clear that a large number of active compounds are unsuitable for  
10 conventional sustained-release formulations and that there is a need for systems which reside in the stomach over a relatively long time and release the active compound there in a controlled manner.

Various mixtures which are based on swellable or  
15 floatable administration forms are described in the patent literature for prolonging the residence time.

Thus US 3574820 and US 4434153, for example, describe tablets which swell in the stomach and thereby become so large that due to their bulkiness they can no longer pass  
20 through the pylorus.

In addition to bulkiness, reduction in density is also used as a measure for prolonging the gastric residence time. Administration forms whose density is lower than that of the stomach contents float and are thus kept away  
25 from the stomach exit, which is located in the lower region of the stomach. JP 62283919 describes, for

example, a tablet comprising a part containing active compound and a part which contains a gas-forming mixture. In contact with aqueous media, carbon dioxide is formed, whereby the average density of the administration form is reduced and the tablet floats on the stomach contents. The reduction of the density by gas formation was also used, as described in EP-A 0235718, with granules of an active compound and a gas-forming mixture coated with a permeable flexible lacquer layer. The abovementioned effects of bulkiness and density reduction due to gas formation are also employed in combination, as shown in Japanese Patent Application 284093/91.

Other administration forms described in the patent literature are not dependent on gas formation for reducing of the density and as a result of their construction already have a density on administration which guarantees the ability to float on the stomach contents. Thus US 3976764 describes systems in all types of embodiments which are constructed such that a hollow core, or a core of low density, was coated with a layer containing active compound. Based on this, EP 0326816 describes administration forms in which the reduction of the density is achieved by the use of structural elements having hollow spaces, such as foams or hollow bodies. Administration forms are described in US 4167558 which essentially consist of a mixture of active compound and gel-forming polymers in a capsule. A gel body which still contains dry powder mixture is formed in the stomach by swelling of the powder mixture after dissolution of the capsule.

The active compound is released in the course of time by erosion of the gel covering. New gel is in this case formed continuously by further swelling of the dry core. The administration form remains capable of floating until  
5 the entire powder mass is soaked through.

Despite the versatility of the mixtures for prolonging the gastric residence time, their conversion to practical pharmaceutical forms is difficult for various reasons. Pure floating pharmaceutical forms such as the pellets  
10 presented above (EP-A-0235718) or systems having an inherent low density (US 3976764, EP-A-0326816 and US 4167558) can only reside in the stomach for a relatively long time if the stomach contains food. In the fasting state, administration forms of this type, due to  
15 their relatively small size, leave the stomach within a short time. In addition, the said administration forms having a low inherent density, due to their relatively low active compound content relative to the volume of the total administration form, are only suitable for low-dose  
20 active compounds. The granules described in EP 0235718 B1 can in turn only be used for water-soluble active compounds, which greatly restricts their use range.

The swellable tablets described in US 3574820, US 4434153 and in JP 284093/91 suffer from the properties of the  
25 swelling matrix used. A good swelling matrix can absorb many times its original weight of moisture. At the same time, however, it must also have a certain dimensional stability in the swollen state in order to stand up to

the mechanical stress to which it is subject in the stomach. Normal linear gel-forming agents such as modified celluloses, polyoxyethylene and polyvinylpyrrolidone (PVP), or alternatively crosslinked polymers, for example based on  
5 PVP or polyacrylates, are indeed distinguished by good liquid absorption, but their dimensional stability greatly decreases with increasing degree of swelling because of the poor association between the hydrated linear polymer chains or crosslinked polymer particles, which leads to the erosion  
10 or to the melting of the gel layer. In JP 284093/91, the administration form was therefore coated with a water-permeable, expandable lacquer. However, this process is complicated and restricts its use to water-soluble active compounds.

15 Gels which consist, as a tablet, of completely crosslinked polymers, as described in US 3574820, have substantially better mechanical properties. Since, however, these crosslinked polymers are new auxiliaries without approval as a pharmaceutical excipient by authorized  
20 institutions like the FDA in the US, the BGA in Germany or other national equivalents, their use is not foreseeable.

Examples of gels are also known in which the crosslinking leading to the gel formation is not based on covalent bonds, but on physicochemical interactions between  
25 various polymers. US 3634584 thus describes gels comprising mixtures of carboxyvinyl polymers and polyethylene glycol and US 3458622 the use of mixtures of PVP and carboxyvinyl polymers in the preparation of administration forms having controlled release of active compound. The gels described,  
30 however, are not

30725-118

distinguished by marked mechanical stability, which already follows from the fact that they are used as an erosion matrix for the controlled release of active compounds. In addition, these gels do not have any marked swelling  
5 properties. JP 334292 describes gels comprising polymers containing amide groups and N-substituted lactams as enzyme carrier systems. These gels also cannot be stressed mechanically, as they dissolve in relatively large volumes of aqueous media.

10           The prior art in general concerns the difficulty of preparing of administration forms having a prolonged gastric residence time and in particular the difficulty of using swellable administration forms based on pharmaceutically acceptable polymers which have a high  
15 dimensional stability in the swollen state and due to their bulkiness reside in the stomach for a relatively long time.

          The present invention relates to administration forms having a relatively long gastric residence time, in the preparation of which mixtures of polymers containing  
20 lactam groups and polymers containing carboxyl groups are used, and which are distinguished both by marked swelling properties and by high dimensional stability in the swollen state.

          In one aspect, the invention provides an  
25 administration form having a prolonged gastric residence time, comprising: (I) an acid insensitive active compound or a combination of two or more acid insensitive active compounds; and (II) a gel-forming agent comprising a homogeneous mixture of polymers (III) containing lactam  
30 groups and polymers (IV) containing carboxyl groups which is

30725-118

distinguished in acidic aqueous media by marked swelling properties.

By "marked swelling properties" is meant that the volume of the administration form, e.g., the tablet, of the invention is increased about five-fold or more. By "high dimensional stability in the swollen state", is meant that the original geometric shape of the administration form, e.g., the tablet is also present in the swollen state. The swollen tablet

looks just like an unswollen tablet seen through a magnifying glass. Moreover, if mechanical force is applied to the swollen tablet, for instance by being pressed in between the mucosa of the stomach it will deform like a sponge but as soon as the pressure is removed it will regain its original shape. The characteristic is not easily measurable but is readily observed.

It has been found that administration forms which, in addition to active compound (I) and auxiliaries (II) customary in pharmacy, contain mixtures of polymers (III) containing  
10 lactam groups and polymers (IV) containing carboxyl groups as gel-forming agents, absorb many times their original weight of water in media having an acidic pH, as is typically present in the stomach, and in contrast to administration forms which contain comparable amounts of a conventional gel-forming agent, swell to give dimensionally stable gels. It is advantageous here if the polymers (III) and (IV) are present in the gel-forming agent in intensively mixed form. The administration forms optionally additionally contain gas-forming agents (V).

The polymers (III) containing lactam groups contained  
20 in the gel-forming agent are compounds based on vinyl-lactams such as vinylcaprolactam and vinylpyrrolidone, which are contained in amounts between 20 and 100% by weight, but preferably between 80 and 100% by weight, relative to the vinyl monomers employed in the preparation. Particularly preferred polymers containing lactam groups within the meaning of the invention are linear polyvinylpyrrolidones having a high molecular weight, such as are marketed, for example, by BASF

under the trade marks "LUVISKOL K 90" or "KOLLIDON K 90". It is preferred to use a polyvinylpyrrolidone that has a weight-average molecular weight that is greater than about 200,000.

The polymers (IV) containing carboxyl groups contained in the gel-forming agent are both polymers containing titratable carboxyl groups which have an acid number between 50 and 1,200 mg of KOH/g, but preferably between 300 and 1,000 mg of KOH/g of polymer solid substance. The acid number indicates how many mg of KOH are necessary for the neutralization of the acidic groups contained in 1 g of dry polymer substance. Examples of such polymers are carboxymethylcellulose, alginates or synthetic polymers based on vinyl monomers, such as acrylic acid, methacrylic acid, maleic acid or fumaric acid. Suitable polymers (IV) containing carboxyl groups include copolymers based on methacrylic acid and methyl methacrylate. It is preferred that the copolymers have a ratio of the free carboxyl groups to the ester groups of about 1:2 or less. A ratio of about 1:1 is particularly preferred.

Particularly preferred polymers containing carboxyl groups within the meaning of the invention are acrylic resins containing carboxyl groups, such as are marketed by Röhm Pharma GmbH under the trade name "EUDRAGIT<sup>®</sup>". Particularly preferred Eudragit grade are "EUDRAGIT L<sup>®</sup>" and "EUDRAGIT S<sup>®</sup>".

The polymers (III) containing lactam groups and the polymers (IV) containing carboxyl groups are present in the administration forms according to the invention in a mixing ratio of between 40:60 and 98:2, but preferably between 80:20

and 95:5. The swelling properties of the administration forms, and also their mechanical stability in the swollen state, is in this case affected substantially by the mixing ratio of the two polymers.

The intensive mixing of the polymers (III) and (IV), which in the end essentially determines the good swelling properties and the mechanical stability of the administration forms prepared therefrom, can be guaranteed, for example, by drying mixed solutions which contain the polymers according to the invention. In this process, the polymer containing carboxyl groups is present in its neutralized form in order to avoid gel formation in the mixed solution. In another method for the preparation of

10

polymer mixtures, a powder mixture of the polymers, optionally provided with active compound and/or other auxiliaries customary in pharmaceutical technology, such as lubricants, binders, fillers etc., is processed by means of suitable methods, e.g. tableting, to give shaped articles of desired geometry, and then stored for a relatively long time at a temperature which should at least be above the glass transition temperature of one of the polymers. This storage causes an intensive molecular association due to interpenetration of the various polymers.

Auxiliaries (II) within the meaning of the invention are those which are necessary to guarantee the preparability of the administration forms or their properties such as hardness, abrasion etc. Among these are, for example, the flow enhancers, fillers, lubricants and binders customary in pharmaceutical practice and known to the expert.

Suitable active compounds or active compound combinations (I) according to the present invention are all those which are suitable for oral administration and for sustained-release therapy. The prerequisite, however, is that they are not acid-sensitive active compounds. The administration forms according to the invention are particularly suitable for active compounds which display their absorption window in the stomach or in the upper part of the gastrointestinal tract, such as ciprofloxacin, nimodipin, captopril and ranitidine, or else display their action there locally, such as certain

antacids. Examples of such antacids are magnesium hydroxide and magnesium trisilicate. Other active ingredients that can be used include cyclosporin, baclofen, allopurinol, furosemide, cefoxitine 5-aminosalicylate and moexipril.

Suitable gas-forming agents (V) which can optionally be employed to increase the buoyancy are all substances which, in contact with water or gastric fluid, are able to form non-toxic gases. Examples are hydrogen carbonates such as, for example, sodium hydrogen carbonate, which are employed  
10 individually, or in combination with acids. Examples of such acids are citric acid or alternatively polyacrylates such as are marketed by B. F. Goodrich Chemical GmbH under the name "CARBOPOL". The gas which forms is incorporated into the hydrated gel layer as bubbles and thus contributes to the buoyancy of the tablet.

The ratios of the amounts of gel-forming agent (III) and (IV) contained in the administration forms according to the invention to active compound (I) or auxiliaries (II) are subject to no restrictions. They depend on the dosage of active  
20 compound, the nature of the active compound and the construction of the administration form. It is essential, however, for the administration form to contain sufficient gel-forming agent so that after administration it can swell up to a size which prevents passage through the pylorus for a relatively long time.

Likewise, the amount of active compound contained in the administration forms according to the invention can also be very different, depending on the nature of the active compound,

the degree of delay of release of the active compound desired and the type of construction of the administration form.

The administration forms according to the invention can be prepared in very different embodiments such as tablets, capsules and granules or pellets. The tablet embodiment, however, is particularly advantageous. The active compound, for example, can thus be compressed together with the polymers according to the invention and optionally other auxiliaries customary in pharmaceutical technology to give a homogeneous  
10 tablet. Systems in a form in which the active compound and the polymers (III) and (IV) are present spatially separated from one another are particularly preferred, however, as is the case, for example, in core-coated tablets having an acentric core exposed on one surface and also in double-layer tablets. A gas-forming mixture can optionally also be incorporated in the administration forms in order to assist the prolongation of the residence time in the stomach due to swelling by means of additional buoyancy.

The invention is further illustrated with reference to  
20 the accompanying drawings. Figures 1 to 4 show, represented schematically as a cross-sectional drawing, examples of different embodiments of the administration forms according to the invention.

Figure 5 is a graph illustrating the swelling of a tablet of the invention as a function of time.

Figure 1 shows an administration form in which the active compound (a) is dissolved in molecular form, or else is incorporated in disperse form in a gel-forming agent (b) based

2143500

23189-7741

on mixtures of polymers (III) containing lactam groups and  
polymers (IV) containing carboxyl groups. The gel-forming agent  
in the types of

construction shown and mentioned below can contain gas-forming agents (V) additionally to the active compound. In the administration form shown in Figure 2, the gel-forming swellable layer (c) and the layer (d) containing the active compound are present separately from one another, in the form of a double-layer tablet. As shown by way of example in Figures 3 and 4, a spatial separation of the two layers can also be achieved using other embodiments. Depending on the solubility of the active compound, one or the other embodiment is to be preferred. An administration form according to Figure 1 is thus particularly suitable for gastric juice-soluble active compounds, and the other embodiments are better suited to insoluble active compounds. It is common to all embodiments, however, that they swell strongly in the stomach and, as a result, reside in the stomach for a relatively long time.

The following examples illustrate the invention.

Example 1

Preparation of the gel-forming agent and the swelling body: Solutions of the polyvinylpyrrolidone Luviskol K 90® (polymer containing lactam groups) and Eudragit L®, a copolymer based on methacrylic acid and methyl methacrylate (polymer containing carboxyl groups), served as a basis for the preparation of the gel-forming agent. 950 g of a 17.5 % strength by weight solution of Luviskol K 90® in water were mixed with 50 g of a 17.5 %

strength aqueous solution of Eudragit L® adjusted to pH 7 with ammonia. The mixed solution was freeze-dried, and the lyophilisate obtained was ground and sieved to 500 micrometres. Tablets having a weight of 400 mg and a diameter of 12 mm were produced from this material by means of a customary eccentric press at a press force of 10 kN.

Determination of the swelling behaviour: The tablets were incubated in 0.1 N HCl at a temperature of 37°C. The tablets were removed from the incubation medium at specific times, the adhering liquid was removed and the weight of the swollen tablets was determined. The degree of swelling ( $Q_t$ ) at the time  $t$  was defined as the quotient of the weight of the tablets at the time  $t$  ( $W_t$ ) and the dry weight of the tablet ( $W_o$ ):

$$Q_t = W_t/W_o$$

The course of the degree of swelling of the tablet described as a function of time is shown graphically in Figure 5.

Determination of the mechanical properties: Stable gels are distinguished in that although they increase in volume during the swelling process, they retain their original shape during the course of this (dimensional stability). In addition, they react to mechanical deformation in a reversible manner, and reassume their original shape after the deforming force is taken away

(high elasticity). Gels of the composition described are distinguished by high dimensional stability and good elastic behaviour.

Comparison Example 2

5     Tablets were prepared having the same composition as in  
Example 1, the gel-forming components not being processed  
as a molecular mixture, prepared by means of solutions,  
however, but as a pure powder mixture. The tablets had  
10    poor mechanical properties in 0.1 N HCl. They were  
strongly sensitive to erosion and dissolved completely in  
the course of time. A determination of the degree of  
swelling ( $Q_t$ ) as a function of time, according to Example  
1, was not possible because of the inadequate mechanical  
strength.

15    Example 3

Tablets containing different ratios of Luviskol K 90® and  
Eudragit L® were prepared according to Example 1 and  
their degree of swelling ( $Q_t$ ) was determined after  
24 hours according to Example 1. The results are summar-  
20    ized in the following table.

Weight ratio Luviskol K 90®:Eudragit L®Degree of swelling Qt  
after 24 hours

	90:10	10.4
	92.5:7.5	12.7
5	95:5	15.3
	96:4	17.2
	97:3	18.2
	98:2	20.4
	100:0	*

10 \*) No gel formation, tablet dissolves completely.

From these data it is evident that the swelling behaviour of the gels can be controlled by the ratio Luviskol K 90®:Eudragit L®. With increasing Eudragit L® content, the gels have an increasing dimensional stability and elasticity. Gels are only formed if both polymeric components are present. Pure PVP is not a stable gel-forming agent.

Comparison Example 4

From the known gel-forming agents listed in the following table, tablets with the same weight and dimensions as in Example 1 were pressed and their degree of swelling (Qt) was determined after 24 hours according to Example 1.

	<u>Polymer</u>	<u>Type</u>	<u>Manufacturer</u>	<u>Degree of swelling (Qt) after 24 hours</u>
	Polyoxyethylene	Polyox Coagulant®	Union Carbide	11.7
	Carboxymethyl-cellulose	Tylose C 6000®	Hoechst	*
5	Hydroxyethyl-cellulose	Tylose H 10,000®	Hoechst	10.3
	Polyacrylate	Carbopol 974 p®	B. F. Goodrich	9.4

\*) Tablet disintegrates within one hour

10 The gel-forming agents mentioned all have poor mechanical properties. They are strongly sensitive to erosion and are deformed irreversibly even with low mechanical stress. On the other hand, the gels described in Example 3 are insensitive to erosion with comparable, or better, swelling behaviour (e.g. gels based on 92.5 parts of PVP

15 K 90 and 7.5 parts of Eudragit L) and exhibit no lasting deformation on mechanical stress due to their high elasticity.

#### Example 5

Preparation of a monolayer tablet according to Figure 1:

20 12 mm tablets of the following composition were prepared

2143500

in an eccentric press at a press force of 10 kN:

<u>Substance used</u>	<u>Amount</u> <u>(mg/tablet)</u>
Ciprofloxacin-HCl	250
Gel mixture prepared according to	229.8
5 Example 1	
(Luviskol K 90®:Eudragit L® = 95:5)	
Sodium bicarbonate powder	20.2

10 The release of active compound from the tablets was determined in a customary release apparatus. In the course of 24 hours the tablets released the active compound completely in 900 ml of 0.1 N HCl at 37°C with continuous stirring (75 revolutions per minute). During the course of this they absorbed so much liquid that their diameter was 3 cm with good mechanical stability

15 according to the criteria mentioned in Example 1.

#### Example 6

20 Preparation of a double-layer tablet according to Figure 2: Double-layer tablets having a diameter of 12 mm, consisting of a swelling layer and an active compound-containing layer, were prepared by the recipe shown below by pressing in an eccentric press at a press pressure of 1.5 tons:

The release of active compound from the tablets was

2143500

determined in a customary release apparatus from ERWEKA. In the course of 7 hours the tablets released 90 % of the active compound linearly in 900 ml of 0.1 N HCl at 37°C with continuous stirring (75 revolutions per minute). The active compound-containing layer dissolved almost completely during the course of this. The swelling layer, on the other hand, increased greatly in volume in the course of time. The diameter was 2 cm after 6 hours and 3 cm after 24 hours. The gel layer was distinguished by good mechanical properties even after 24 hours. It was reversibly deformable on mechanical stress and exhibited no visible erosion. As a result of gas formation due to the sodium bicarbonate contained in the gel layer, the tablet drifted to the surface of the release medium during the release.

	<u>Substance used</u>	<u>Amount (mg/tablet)</u>
	<u>Swelling layer</u>	
	Gel mixture prepared according to Example 1	340
20	(Luviskol K 90®:Eudragit L® =95.5)	
	Carbopol 974 P	34
	Magnesium stearate	10
	Red iron oxide	2.5
	Sodium bicarbonate	34
25	<u>Active compound-containing layer</u>	
	Ciprofloxacin HCl	250
	Magnesium stearate	2.9
	Klucel JF® (hydroxypropylcellulose)	80

30725-118

CLAIMS:

1. An administration form having a prolonged gastric residence time, comprising:

(I) an acid insensitive active compound or a combination of  
5 two or more acid insensitive active compounds; and

(II) a gel-forming agent comprising a homogeneous mixture of polymers (III) containing lactam groups and polymers (IV) containing carboxyl groups

which is distinguished in acidic aqueous media by marked  
10 swelling properties.

2. The administration form according to claim 1, which further comprises an auxiliary customary in pharmacy.

3. The administration form according to claim 1 or 2, which further comprises a gas-forming additive.

15 4. The administration form according to any one of claims 1 to 3, wherein the gel-forming agent contains the polymers (III) and (IV), containing lactam groups and carboxyl groups in molecularly mixed form.

5. The administration form according to any one of  
20 claims 1 to 4, wherein the polymer (III) contains monomers containing lactam groups, based on vinyl monomers employed in the preparation of the polymer, in amounts between 20 and 100% by weight.

6. The administration form according to any one of  
25 claims 1 to 5, wherein the polymer (III) contains monomers containing lactam groups, based on vinyl monomers employed in the preparation of the polymer, in amounts between 80 and 100% by weight.

30725-118

7. The administration form according to any one of claims 1 to 6, wherein the polymer (III) containing lactam groups is a polyvinylpyrrolidone having a weight-average molecular weight  $> 200,000$ .
- 5 8. The administration form according to any one of claims 1 to 7, wherein the polymer (IV) containing carboxyl groups has an acid number between 100 and 1,200 mg of KOH/g of polymer solid substance.
9. The administration form according to any one of  
10 claims 1 to 8, wherein the polymer (IV) containing carboxyl groups is a copolymer based on methacrylic acid and methyl methacrylate, having a ratio of the free carboxyl groups to the ester groups of about 1:2.
10. The administration form according to any one of  
15 claims 1 to 8, wherein the polymer (IV) containing carboxyl groups is a copolymer based on methacrylic acid and methyl methacrylate, having a ratio of the free carboxyl groups to the ester groups of about 1:1.
11. The administration form according to any one of  
20 claims 1 to 10, wherein the polymers (III) containing lactam groups and the polymers (IV) containing carboxyl groups are present in a mixing ratio of between 40:60 and 98:2.
12. The administration form according to claim 11, wherein the polymers (III) containing lactam groups and the  
25 polymers (IV) containing carboxyl groups are present in a mixing ratio of between 80:20 and 95:5.
13. The administration form according to any one of claims 1 to 10 and 12, wherein the active compounds or active compound combinations I contained therein have an  
30 absorption window in the stomach or in the upper part of the

30725-118

gastrointestinal tract, or else display their action locally in the stomach or upper part of the human gastrointestinal tract.

14. The administration form according to any one of  
5 the claims 1 to 10 and 12, wherein the acid insensitive active compound is ciprofloxacin, nimodipine, captopril, ranitidine, cyclosporin, baclofen, allopurinol, furosemide, cefoxitine, 5-aminosalicylate or moexipril.

15. The administration form according to any one of  
10 claims 1 to 10 and 12, wherein the acid insensitive active compound contained therein is an antacid.

16. The administration form according to claim 15, wherein the antacid is magnesium hydroxide or magnesium trisilicate.

15 17. A pharmaceutical composition having a prolonged gastric residence time, which composition comprises an acid insensitive active ingredient and a homogeneous mixture of a polymer containing lactam groups and a polymer containing carboxyl groups.

20 18. A process for preparing a pharmaceutical composition according to claim 17, which process comprises forming a solution containing a polymer containing lactam groups and a polymer containing carboxyl groups, removing the solvent to form a homogeneous mixture of the polymer  
25 containing the lactam groups and the polymer containing the carboxyl groups and admixing the said homogeneous mixture with the acid insensitive active ingredient.

19. The process for preparing a pharmaceutical composition according to claim 17, which process comprises  
30 admixing a polymer containing lactam groups with a polymer

30725-118

containing carboxyl groups, storing the polymer mixture at a temperature that is above the glass transition temperature of one or both of the polymers for a time sufficient for the mixture to become homogeneous, and admixing the said  
5 homogeneous mixture with the active ingredient.

FETHERSTONHAUGH & CO.  
OTTAWA, CANADA

PATENT AGENTS